NICE issues final guidance on NHS use of Bayer’s Vitrakvi
Evidence from trials suggests that tumours with NTRK gene fusions shrink in response to larotrectinib
Read More
Tag: Vitrakvi
NICE backs NHS use of Bayer’s Vitrakvi via the CDF
The drug was initially considered too expensive but its cost to the NHS has been lowered
Read More
Vitrakvi deemed ‘not cost-effective’ by NICE
The organisation, however, encourages further data collection on similar “game changing” histology independent cancer drugs.
Read More
EU nod for Bayer’s Vitrakvi
European regulators have cleared Bayer’s Vitrakvi (larotrectinib) as a treatment for solid tumours displaying an NTRK gene fusion.
Read More
Eli Lilly to buy Loxo Oncology for $8 billion
Eli Lilly has announced its intention to buy pioneering cancer treatment development company Loxo Oncology in a deal worth approximately $8 billion.
Read More
US approves first ever TRK inhibitor
Bayer and Loxo Oncology’s Vitrakvi has become the first ever TRK inhibitor to be approved in the US, having been cleared to treat advanced solid tumours harbouring an NTRK gene fusion.
Read More
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
